GlassScriptPhysician profile
Stephen J Roth
NPI 1801075239
$4,603.83
in general payments reported to CMS, 2019-2025
40 companies · $1,134 in 2025
The $1,134 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,236 · 2020: $503 · 2021: $111 · 2022: $130 · 2023: $525 · 2024: $964 · 2025: $1,134.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,624.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,624.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,182.07 | 2021-2025 | Qulipta, Botox, Duopa |
| Biogen, INC. | $423.77 | 2019-2025 | Vumerity, Tysabri |
| Novartis Pharmaceuticals Corporation | $296.27 | 2019-2024 | |
| Supernus Pharmaceuticals, INC. | $275.89 | 2019-2025 | Qelbree |
| Medtronic, INC. | $259.02 | 2023-2025 | Cd Horizon Spinal System, Percept PC Brainsense |
| Alexion Pharmaceuticals, INC. | $250.58 | 2019-2025 | Ultomiris |
| Genzyme Corporation | $191.02 | 2019-2020 | |
| Acadia Pharmaceuticals INC | $162.00 | 2019-2025 | Nuplazid |
| Ucb, INC. | $128.53 | 2019-2025 | Zilbrysq, Fintepla |
| Mallinckrodt Enterprises LLC | $121.01 | 2019 | |
| Lilly USA, LLC | $105.76 | 2019-2025 | Kisunla |
| Otsuka America Pharmaceutical, INC. | $97.32 | 2023-2025 | Rexulti, Nuedexta |
| Emd Serono, INC. | $83.42 | 2019-2020 | |
| Pfizer INC. | $79.55 | 2024-2025 | |
| Amgen INC. | $77.26 | 2024-2025 | Uplizna |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Roth listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.